News & Information
 

Intralytix's CSO Appointed Editor-In-Chief of New Phage Journal

PRESS RELEASE - 02/09/2011

Baltimore, Maryland, U.S.A. - February 9, 2011 - Intralytix, Inc. announced today that its Chief Scientific Officer, Dr. Alexander Sulakvelidze, has been appointed Editor-In-Chief of a new scientific journal called "Bacteriophage."

Bacteriophage is an international, peer-reviewed journal that publishes original research papers, reviews, and commentaries relevant to all aspects of bacteriophage research, ranging from basic phage biology and taxonomy to advanced bacteriophage-host cell interactions and various practical applications of bacteriophages. The first issue of the journal is currently in print. It can be also viewed on the journal's web site, at: http://www.landesbioscience.com/journals/bacteriophage/

Dr. Alexander "Sandro" Sulakvelidze is one of the founders of Intralytix and holds the title of Vice President, Research and Development, as well as Chief Scientific Officer. "We are proud of this recognition of Dr. Sulakvelidze's expertise and leadership in the field of bacteriophage," stated John Woloszyn, Intralytix's CEO. "We are confident that under Dr. Sulakvelidze's leadership, Bacteriophage will play an important role in the advancement of this vital technology and science" he added.

Intralytix, Inc is a biotechnology company focused on using its core bacteriophage/phage technology platform to improve human health through the development and commercialization of innovative products for food safety and human therapeutics.

For more information, contact Mr. John Woloszyn (410-625-3813 or jwoloszyn@intralytix.com) or Dr. Alexander Sulakvelidze (410-625-2533 or asulakvelidze@intralytix.com).

To submit a paper to Bacteriophage, visit: http://bacteriophage.msubmit.net. For questions concerning Bacteriophage, contact Kathryn Sauceda, Managing Editor: kat@landesbioscience.com.

Feb 09, 2011

Back to news archive



Technology

Food Safety

Environmental Sanitation

Veterinary Applications

Human Therapeutics

Probiotics